Digest Network Come funziona
Network
/
Società
Al
Non verificato

Alnylam Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteWeb e Social Network

37 comunicati stampa

Guarda tutti i comunicati
09/06/2025
Scienza
Cardiologia
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Mercato del lavoro
Industria
Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1,00
0
28/05/2025
Biotecnologia
Farmaceutica
Salute
Sanità
Eventi
Web e Social Network
Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1,00
0
20/05/2025
Responsabilità sociale d'impresa
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Alnylam Issues 2024 Corporate Responsibility Report
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1,00
0
17/05/2025
Eventi
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Cardiologia
Biotecnologia
AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1,00
0
12/05/2025
Eventi
Industria
Scienza
Biotecnologia
Medicina - Varie
Cardiologia
Sanità
Farmaceutica
Salute
Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1,00
0
05/05/2025
Eventi
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1,00
0
01/05/2025
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1,00
0
28/04/2025
Industria
Cardiologia
Biotecnologia
Igiene alimentare
Salute
Sanità
Farmaceutica
Scienza
Medicina - Varie
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1,00
0
17/04/2025
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Sanità
Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1,00
0
01/04/2025
Eventi
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference
Fonte
Alnylam Pharmaceuticals, Inc.
Emittente
Business Wire
1,00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0